MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2024015415

Медицинская библиотека · Blood advances · 2025

Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study.

Bento Leyre, Gutiérrez Antonio, Martínez Carmen, Ortí Verdet María Consejo, Sorribes Marina, Caballero Ana Carolina, Peña Marta, Pérez Ariadna, Jiménez-Ubieto Ana, Medina Lucía, Bastos-Oreiro Mariana, Caldas-González Paula Fernández, Navarro Belén, Salcedo Isabel, Abrisqueta Pau, Español Ignacio, Cornago Javier, Martín-Moro Fernando, García Lucía, Gómez Pilar, Varela María Rosario, Puente María, Zanabili Joud, Zudaire Teresa, Zeberio Izaskun, Del Campo Raquel, González Leslie, González Pedro, Blázquez Cristina, Rovira Jordina, Sitges Marta, Franch-Sarto Mireia, Cabero Almudena, Mussetti Alberto, Montoro Juan, Sampol Antonia, Sureda Anna, Caballero Dolores, Martín García-Sancho Alejandro

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

We performed a retrospective multicenter study including 791 patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who underwent autologous stem cell transplantation (ASCT). After a median follow-up of 74 months from infusion, 65% were alive and 84% free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% and 63%, respectively. Non-relapse mortality at 1 year was 9%. Age >60 years at ASCT (hazard ratio [HR], 1.31; 95% CI, 1.06-1.62; P = .011), ASCT as ≥3rd line (HR, 1.81; 95% CI, 1.42-2.31; P < .001), and partial response (PR) vs complete response (CR) at ASCT (HR, 1.46; 95% CI. 1.18-1.81; P < .001) were independent variables influencing PFS. Age >60 years at ASCT (HR, 1.62; 95% CI, 1.24-2.12; P < .001), time period before 1 November 2012 (HR, 1.40; 95% CI, 1.07-1.83; P = .014), ASCT as ≥3rd line (HR, 1.77; 95% CI, 1.32-2.37; P < .001), PR vs CR (HR, 1.58; 95% CI, 1.22-2.05; P < .001), and stable disease vs CR pre-ASCT (HR, 3.41; 95% CI, 1.81-6.45; P < .001) were variables associated with worse OS. Refractory/early relapse did not significantly influence survival (6-year PFS and OS in patients with refractory, early, and late relapse were 54% and 64%, 46% and 62%, and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease.

Для цитирования: Bento Leyre, Gutiérrez Antonio, Martínez Carmen, Ortí Verdet María Consejo, Sorribes Marina, Caballero Ana Carolina, Peña Marta, Pérez Ariadna, Jiménez-Ubieto Ana, Medina Lucía, Bastos-Oreiro Mariana, Caldas-González Paula Fernández, Navarro Belén, Salcedo Isabel, Abrisqueta Pau, Español Ignacio, Cornago Javier, Martín-Moro Fernando, García Lucía, Gómez Pilar, Varela María Rosario, Puente María, Zanabili Joud, Zudaire Teresa, Zeberio Izaskun, Del Campo Raquel, González Leslie, González Pedro, Blázquez Cristina, Rovira Jordina, Sitges Marta, Franch-Sarto Mireia, Cabero Almudena, Mussetti Alberto, Montoro Juan, Sampol Antonia, Sureda Anna, Caballero Dolores, Martín García-Sancho Alejandro. Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study.. Blood advances. 2025. DOI: 10.1182/bloodadvances.2024015415.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.